The Charge of the Teaching Brigade: The New ASH Medical Educators Institute
Dr. Kesselheim and Dr. Kahn share important details and information about the brand new ASH Medical Educators Institute.
Born to Friends
Dr. Moss reviews the often-raised question of how we select a donor for a patient who needs a stem cell transplant and the three main options, which include an HLA-matched
Dr. Moss covers the often-raised question of how to select a donor for a patient who needs a stem cell transplant and three options for transplantation.
Dr. LaCasce discusses the use of recently FDA-approved drug venetoclax to treat patients with CLL. Dr. Andrew Roberts joins her for this podcast.
Dr. Abrams discusses the "National Cancer Moonshot" which covers advancements in cancer therapy currently underway.
May/June 2016 Volume 13, Issue 3
View all Features articles
View all Diffusion articles
Dr. Charles Abrams discusses the "National Cancer Moonshot" which covers advancements in cancer therapy that are currently underway and ASH's efforts in influencing this dialogue.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
The Centers for Medicare and Medicaid Services (CMS) released the annual set of proposals governing payments for services provided to patients admitted to the hospital, commonly referred to as the hospital inpatient prospective payment system (IPPS). ASH explores how this will affect hematologists.
As part of the American Society of Hematology’s (ASH)
multifaceted initiative to address the burden of sickle cell disease, ASH is in
the process of working with stakeholders to improve access to care for
individuals with sickle cell disease.
Included in this effort is
On March 8, 2016, the Center for Medicare and Medicaid Services (CMS) proposed a new experiment in payment rates for physician-administered drugs such as chemotherapy. This plan would change the current formula for drug payment so that payments for expensive drugs are reduced in certain areas of the country. In a second phase, CMS would be able to adopt certain tools to further adjust pricing for drugs.
ASH submitted comments to the National Heart, Lung and Blood Institute (NHLBI) on its recently released draft strategic research priorities that will inform the Institute’s policy and funding decisions for the next several years. ASH’s comments were developed based on the ASH Agenda for Hematology Research and input from members of the ASH Committee on Scientific Affairs and ASH Scientific Committees.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology